News
Novartis receives vital licence for Scemblix
Novartis UK has announced that Scemblix – also known as asciminib – has been granted marketing authorisation in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Novartis UK has announced that Scemblix – also known as asciminib – has been granted marketing authorisation in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).